Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes. | MicrobiomeTrials← Back to trialsNCT07619508
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
RecruitingOBSERVATIONAL
Trial Details
Start: 2026-02-10Est. Completion: 2026-06-01
Enrollment target: 100,000 participants Locations- Brigham and Women's Hospital, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Insulin ResistanceObesity
Background:
Obesity and related illnesses cause at least 2.8 million deaths each year worldwide. Few treatments exist f…
Bethesda, United StatesEst. completion Mar 1, 2030
Serious Mental Illness
This project addresses obesity in the population with SMI by evaluating a weight management program that is not only evi…
Pittsburgh, United StatesCompleted Sep 30, 2025
ENROLLING_BY_INVITATION
ExercisePhysical ActivityGamificationUniversity StudentCollege Student
The increasing incidence of cardiovascular disease (CVD) and related mortality is now recognized as a global emergency. …
Bursa, Turkey (Türkiye)Completed Mar 20, 2026